Home > Healthcare > Pharmaceuticals > Finished Drug Form > Sulphonamides Market

Sulphonamides Market Trends

  • Report ID: GMI9708
  • Published Date: May 2024
  • Report Format: PDF

Sulphonamides Market Trends

The elevated cases of bacterial infections, including hospital-acquired infections (HAIs), resulted in an ongoing need for effective antibiotics to address and resolve these diseases, thereby driving up the demand for sulphonamides. HAIs, often caused by resistant bacteria, pose significant health risks and complications for patients. Sulphonamides, known for their broad-spectrum antibacterial properties, are frequently used to combat these infections bolstering the market demand.
 

  • For instance, the NHS and UK Health Security Agency (UKHSA) are highlighting the prevalence of UTIs, with recent data revealing over 800,000 hospital admissions in the past five years. Between 2018-19 and 2022-23, there were over 1.8 million admissions, predominantly among individuals aged 65 and above. Thus, the ongoing occurrence of HAIs ensured a persistent demand for effective antibiotics including sulphonamides, striving to reduce infection rates and improve patient outcomes.
     

Moreover, advancing healthcare infrastructure, antibiotic resistance, raising awareness campaigns, and intensified research and development activities further accelerate the demand for sulphonamides in the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of sulphonamides was reached USD 122.4 million in 2023 and will grow at 4.8% CAGR from 2024 to 2032, driven by the increasing prevalence of infectious diseases globally.

The oral administration mode segment of the sulphonamides market recorded USD 66.2 million in 2023 and will reach USD 98.6 million by 2032, as it offers convenient administration, facilitating patient compliance and ensuring timely treatment initiation.

U.S. sulphonamides market size accounted for USD 48 million in 2023 and is anticipated to show significant growth, due to high prevalence and incidence of infectious diseases.

Aurobindo Pharma, Bausch & Lomb Incorporated, Cadila Pharmaceuticals Ltd, Cipla Ltd, Dr. Reddy’s Laboratories, F. Hoffmann-La Roche Ltd, GSK PLC, Glenmark Pharma Ltd, and Lexine Technochem Pvt. Ltd. among others.

Sulphonamides Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 15
  • Tables & Figures: 259
  • Countries covered: 22
  • Pages: 242
 Download Free Sample